Regenxbio

RGNX NASDAQ
50.12
-0.47
-0.93%
交易中 11:59 07/23 EDT
开盘
50.76
昨收
50.59
最高
50.76
最低
49.55
成交量
8.76万
成交均量(3M)
54.27万
52周最高
83.45
52周最低
38.56
换手率
0.24%
市值
18.36亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Regenxbio RGNX股票价格,Regenxbio股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
展开 >

最近浏览

名称
价格
涨跌幅